Doubt Grows on Celgene Deal as a Bristol-Myers Holder Balks

(Bloomberg) -- Doubts are beginning to gather around the pharmaceutical industry’s biggest-ever takeover after Bristol-Myers Squibb Co.’s second-largest shareholder said that it doesn’t favor a $74...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.